Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in Iran to treat respiratory problems such as asthma and chronic obstructive pulmonary disease (COPD). The market for these drugs in Iran has been growing steadily over the past few years, driven by various factors.
Customer preferences: Iran has a high prevalence of respiratory diseases, particularly asthma, which has led to an increase in demand for bronchodilator drugs. Patients in Iran prefer using inhalers, which are more effective and have fewer side effects than oral medications.
Trends in the market: The market for bronchodilator drugs in Iran is expected to continue growing due to the increasing prevalence of respiratory diseases and the government's efforts to improve healthcare access. The market is highly competitive, with both domestic and international players vying for market share.
Local special circumstances: Iran's healthcare system is heavily subsidized by the government, which has led to affordable healthcare for the population. However, the sanctions imposed by the US have made it difficult for international pharmaceutical companies to do business in Iran, leading to a rise in domestic production of bronchodilator drugs.
Underlying macroeconomic factors: Iran's economy has been struggling due to the sanctions and the COVID-19 pandemic, leading to a depreciation of the Iranian rial and inflation. This has made it difficult for patients to afford expensive imported medications, leading to an increase in demand for locally produced bronchodilator drugs.In conclusion, the market for bronchodilator drugs in Iran is expected to continue growing due to the high prevalence of respiratory diseases and the government's efforts to improve healthcare access. The market is highly competitive, with both domestic and international players vying for market share. The sanctions imposed by the US have led to a rise in domestic production of bronchodilator drugs, and the struggling economy has made it difficult for patients to afford expensive imported medications.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
